Bright Green Corporation (BGXXQ) Fair Value & Analysis
Health Care · US · Market cap $7.3M
Bright Green Corporation
BGXXQ · US
Fair value as of: Aug 16, 2026
From 1 valuation models · updated today
Fair value updated Aug 16, 2026, revised from $0.0100 to $0.0003 (−97.0%) since Jun 23, 2026. Share price −60.0% over the past month.
Below-average quality, screening 50% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (23/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($0.0003). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 16, 2026.
How to read this chart
51‑month range $0.0002 – $48.08 · the $0.0002 price screens below the $0.0003 fair value. Dashed = 300-day average. As of Aug 16, 2026.
Analysis
Bright Green Corporation (BGXXQ) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0003, implying the stock looks roughly 50.0% undervalued today. The Quality Score stands at 23/100 (below-average quality), in the Health Care sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
It earns a return on equity of -73.6%. Net debt stands at $1.8M. Fundamentals as of Aug 16, 2026
For context, the median of 10 Health Care peers we cover trades at -14% fair-value upside, at 50%, BGXXQ screens cheaper than that median.
Notify me when BGXXQ reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 26 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bright Green Corporation produces and exports legal cannabis, cannabis extracts, and tetrahydrocannabinol in the United States. Its products are used in research, manufacturing, and export, as well as for production of medical cannabis products and preparations. The company was incorporated in 2019 and is based in Grants, New Mexico.
Full company description
Bright Green Corporation produces and exports legal cannabis, cannabis extracts, and tetrahydrocannabinol in the United States. Its products are used in research, manufacturing, and export, as well as for production of medical cannabis products and preparations. The company was incorporated in 2019 and is based in Grants, New Mexico. On February 22, 2025, Bright Green Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Mexico.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Bright Green Corporation reported revenue of $401K in FY2023 versus $0 in FY2020. Reported net income was −$13.1M in FY2023.
Watch BGXXQ: get an alert when its fair value changes →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Torrent Pharmaceuticals Limited 500420 | ₹4,876 | ₹4,360 | -11% |
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,620 | ₹1,452 | -45% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| Oscotec Inc 039200 | 38,800 KRW | 33,210 KRW | -14% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| Kolon Life Science Inc 102940 | 17,460 KRW | 37,129 KRW | +113% |
| Huons Global Co 084110 | 25,100 KRW | 58,482 KRW | +133% |
| BINEX Co 053030 | 7,300 KRW | 1,844 KRW | -75% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 15,520 KRW | 4,741 KRW | -69% |
Compare Bright Green Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bright Green Corporation (BGXXQ) overvalued or undervalued?
What is the fair value of BGXXQ?
What is the quality score of BGXXQ?
What is the net profit margin of BGXXQ?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bright Green Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.